Archive \ Volume.13 2022 Issue 3

Polypharmacy and Medication Compliance among Patients with Type 2 Diabetes in Oman: A Cross-Sectional Study

Asma Al Shidhani , Asma Al Salmani , Yaqoub Al Saidi , Marwa Al Shehhi , Hoor Al Khanjari , Mahla Al Aamri , Fatma Al Hadabi
Abstract

The goal of this study was to estimate the prevalence of polypharmacy and medication compliance among patients with T2DM at a primary care clinic in Muscat, Oman, to determine whether various sociodemographic and clinical factors were associated with polypharmacy and to assess relationships between polypharmacy, compliance, and self-related health. It is a cross-sectional study conducted between September and November 2019 and included all adult T2DM patients attending the clinic. Data were collected using a questionnaire, face-to-face interviews, and electronic medical records. A total of 202 T2DM patients were included. The majority were female (56.9%) and ≥60 years old (45.5%). Most had two or more chronic health conditions (66.3%). The prevalence of polypharmacy was 83.1%. Overall, 65% and 92% of patients reported a high level of adherence to treatment and good-to-excellent health, respectively. In conclusion, Polypharmacy was common among T2DM patients and was significantly associated with age, common comorbidities, and T2DM duration.



How to cite:
Vancouver
Al Shidhani A, Al Salmani A, Al Saidi Y, Al Shehhi M, Al Khanjari H, Al Aamri M, et al. Polypharmacy and Medication Compliance among Patients with Type 2 Diabetes in Oman: A Cross-Sectional Study. Arch. Pharm. Pract. 2022;13(3):48-53. https://doi.org/10.51847/zimW7hb8OD
APA
Al Shidhani, A., Al Salmani, A., Al Saidi, Y., Al Shehhi, M., Al Khanjari, H., Al Aamri, M., & Al Hadabi, F. (2022). Polypharmacy and Medication Compliance among Patients with Type 2 Diabetes in Oman: A Cross-Sectional Study. Archives of Pharmacy Practice, 13(3), 48-53. https://doi.org/10.51847/zimW7hb8OD

Download Citation
References

1.        Noale M, Veronese N, Perin PC, Pilotto A, Tiengo A, Crepaldi G, et al. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta Diabetol. 2016;53(2):323-30. doi:10.1007/s00592-015-0790-4

2.        Lee EA, Brettler JW, Kanter MH, Steinberg SG, Khang P, Distasio CC, et al. Refining the Definition of Polypharmacy and Its Link to Disability in Older Adults: Conceptualizing Necessary Polypharmacy, Unnecessary Polypharmacy, and Polypharmacy of Unclear Benefit. Perm J. 2020;24:18.212. doi:10.7812/TPP/18.212

3.        Good CB. Polypharmacy in elderly patients with diabetes. Diabetes Spectr. 2002;15(4):240-8. doi:10.2337/diaspect.15.4.240

4.        Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2007; 24(1):14-9. doi:10.1093/fampra/cml067

5.        Slater N, White S, Venables R, Frisher M. Factors associated with polypharmacy in primary care: A cross-sectional analysis of data from The English Longitudinal Study of Ageing (ELSA). BMJ Open. 2018;8(3):e0202701. doi:10.1136/bmjopen-2017-020270

6.        Lim LM, McStea M, Chung WW, Azmi NN, Abdul Aziz SS, Alwi S, et al. Prevalence, risk factors, and health outcomes associated with polypharmacy among urban community-dwelling older adults in multi-ethnic Malaysia. PLoS One. 2017;12(3):e0173466. doi:10.1371/journal.pone.0173466

7.        Kim HA, Shin JY, Kim MH, Park BJ. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One. 2014;9(6):e98043. doi:10.1371/journal.pone.0098043

8.        Alsuwaidan A, Almedlej N, Alsabti S, Daftardar O, Al Deaji F, Al Amri A, et al. A comprehensive overview of polypharmacy in elderly patients in Saudi Arabia. Geriatrics. 2019;4(2):36.  doi:10.3390/geriatrics4020036

9.        Bradley D, Hsueh W. Type 2 diabetes in the elderly: Challenges in a unique patient population. J Geriatr Med Gerontol 2016;2(2):14. doi:10.23937/2469-5858/1510014

10.      Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843

11.      Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 2016;24(1):51-62. doi:10.1016/j.cmet.2016.06.021

12.      Dobrică EC, Găman MA, Cozma MA, Bratu OG, Stoian AP, Diaconu CC. Polypharmacy in type 2 diabetes mellitus: Insights from an internal medicine department. Medicina (Kaunas). 2019;55(8):436. doi:10.3390/medicina55080436

13.      Alwhaibi M, Balkhi B, Alhawassi TM, Alkofide H, Alduhaim N, Alabdulali R, et al. Polypharmacy among patients with diabetes: A cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open. 2018;8:e020852. doi:10.1136/bmjopen-2017-020852

14.      Feng X, Tan X, Riley B, Zheng T, Bias TK, Becker JB. Prevalence and geographic 14 variations of polypharmacy among West Virginia Medicaid beneficiaries. Ann Pharmacother. 2017;51(11):981-9. doi:10.1177/1060028017717017

15.      Horii T, Iwasawa M, Kabeya Y, Atuda K. Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterized by drug class and patient characteristics: A Japanese database analysis. Sci Rep. 2019;9(1):12992.  doi:10.1038/s41598-019-49424-2

16.      Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74. doi:10.1097/00005650-198601000-00007

17.      Vyas A, Kang F, Barbour M. Association between polypharmacy and health-related quality of life among US adults with cardiometabolic risk factors. Qual Life Res. 2020; 29(4):977-86. doi:10.1007/s11136-019-02377-5

18.      Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187-95. doi:10.1111/j.1365-2125.2006.02744.x

19.      Gadsby R, Galloway M, Barker P, Sinclair A. Prescribed medicines for elderly frail people with diabetes resident in nursing homes: Issues of polypharmacy and medication costs. Diabet Med. 2012;29(1):136-9. doi:10.1111/j.1464-5491.2011.03494.x

20.      Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5):1408-12. doi:10.2337/diacare.26.5.1408

21.      Abu Farha RK, Mukattash TL, Al-Sakran L, Abu Hammour K, Zawiah M. Prevalence and predictors of polypharmacy in Jordanian hospitalised patients: A cross-sectional Study. Int J Clin Pract. 2021;75(4):e13742. doi:10.1111/ijcp.13742

22.      Balkhi B, AlQahtani N, Alwhaibi M, Alshammari TM, Alhawassi TM, Mahmoud MA, et al. Prevalence and Factors Associated With Polypharmacy Use Among Adult Patients in Saudi Arabia. J Patient Saf. 2021;17(8):e1119-24. doi:10.1097/PTS.0000000000000439

23.      Iglay K, Hannachi H, Howie PJ, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243-52. doi:10.1185/03007995.2016.1168291

24.      Li J, Chattopadhyay K, Xu M, Chen Y, Hu F, Wang X, et al. Prevalence and predictors of polypharmacy prescription among type 2 diabetes patients at a tertiary care department in Ningbo, China: a retrospective database study. PLoS One. 2019;14(7):e0220047. doi:10.1371/journal.pone

25.      Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: Mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich). 2011;13(4):244-51. doi:10.1111/j.1751-7176.2011.00434.x

26.      Rieckert A, Trampisch US, Klaaßen-Mielke R, Drewelow E, Esmail A, Johansson T, et al. Polypharmacy in older patients with chronic diseases: A cross-sectional analysis of factors associated with excessive polypharmacy. BMC Fam Pract. 2018;19(1):113. doi:10.1186/s12875-018-0795-5

27.      Bierman AS, Pugh MJ, Dhalla I, Amuan M, Fincke BG, Rosen A, et al. Sex differences in inappropriate prescribing among elderly veterans. Am J Geriatr Pharmacother. 2007;5(2):147-61. doi:10.1016/j.amjopharm.2007.06.005

28.      Zelko E, Klemenc-Ketis Z, Tusek-Bunc K. Medication adherence in elderly with polypharmacy living at home: A systematic review of existing studies. Mater Sociomed. 2016;28(2):129-32. doi:10.5455/msm.2016.28.129-132

29.      Cárdenas-Valladolid J, Martín-Madrazo C, Salinero-Fort MA, de-Santa Pau EC, Abánades-Herranz JC, de Burgos-Lunar C. Prevalence of adherence to treatment in homebound elderly people in primary health care: A descriptive, cross-sectional, multicentre study. Drugs Aging. 2010;27(8):641-51. doi:10.2165/11537320-000000000-00000

30.      Badawi G, Gariépy G, Pagé V, Schmitz N. Indicators of self-rated health in the Canadian population with diabetes. Diabet Med 2012;29(8):1021-8. doi:10.1111/j.1464-5491.2012.03571.x

31.      Bazargan M, Smith J, Saqib M, Helmi H, Assar S. Associations between polypharmacy, self-rated health, and depression in African American older adults: Mediators and moderators. Int J Environ Res Public Health. 2019;16(9):1574. doi:10.3390/ijerph16091574